Delivery systems: A vaccine strategy for overcoming mucosal tolerance?

Expert Review of Vaccines

Volumn 8, Issue 1, 2009, Pages 103-112

  Mann, Jamie F S ^b   Acevedo, Reinaldo ^c   Del Campo, Judith ^c   Pérez, Oliver ^c   Ferro, Valerie A ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c FINLAY INSTITUTE   (Cuba)

Author keywords

Adjuvant; Delivery system; Mucosal immunization; Tolerance; Vaccine

Indexed keywords

ALZHEIMER DISEASE VACCINE; ANTHRAX VACCINE; AVIAN INFLUENZA VACCINE; BOTULINUM TOXIN; BT VACC; HEPATITIS B VACCINE; INFLUENZA VACCINE; ISCOM; ISCOMATRIX; LIPOSOME; MENINGOCOCCUS VACCINE; NASALFLU; PHOSPHOLIPID DERIVATIVE; PROTOLLIN; ROTAVIRUS VACCINE; TETANUS TOXOID; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACCINE;

DRUG DELIVERY SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEOLIPOSOME; REVIEW; SINGLE DRUG DOSE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; HUMANS; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; VACCINATION; VACCINES;

EID: 58149380346     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.8.1.103     Document Type: Review

References (99)

1. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25(30), 5467-5484 (2007). •• Provides understanding of the importance of the role of secretory IgA in mucosal immunity and discusses the need for more work in vaccine and adjuvant design.
2. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2(8), 725-731 (2001).
3. Challacombe SJ, Tomasi TB. Systemic tolerance and secretory immunity after oral immunization. J. Exp. Med. 152, 1459-1472 (1980).
4. Fujihashi K, Kato H, Van Ginkel FW et al. A revisit of mucosal IgA immunity and oral tolerance. Acta Odontol. Scand. 59, 301-308 (2001).
5. Abbas AK, Sharpe AH. Dendritic cells giveth and taketh away. Nat. Immunol. 6(3), 227-228 (2005).
6. Cutler CW, Jotwani R. Dendritic cells at the oral mucosal interface. J. Dent. Res. 85(8), 678-689 (2006).
7. Iwata M, Eshima Y, Kagechika H. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21(4), 527-538 (2004).
8. Mestecky J, Russell MW, Elson CO. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J. Immunol. 179(9), 5633-5638 (2007). •• Provides useful insight into the hurdles that must overcome in order to achieve efficacy with mucosal vaccines without invoking tolerance.
9. Montalto M, Santoro L, D'Onofrio F et al. Adverse reactions to food: allergies and intolerances. Dig. Dis. 26(2), 96-103 (2008).
10. Niewinski MM. Advances in celiac disease and gluten-free diet. J. Am. Diet Assoc. 108(4), 661-672 (2008).
11. Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol. Clin. North Am. 34(2), 247-255 (2005).
12. Garside P, Millington O, Smith KM. The anatomy of mucosal immune responses. Ann. NY Acad. Sci. 1029, 9-15 (2004). •• Excellent overview of the interactions of fed antigen with different effector sites and immune cells.
13. Smith DW, Nagler-Anderson C. Preventing intolerance: the induction of nonresponsiveness to dietary and microbial antigens in the intestinal mucosa. J. Immunol. 174(7), 3851-3857 (2005).
14. Brandtzaeg P, Pabst R. Let's go mucosal: communication on slippery ground. Trends Immunol. 25, 570-577 (2005). •• Excellent paper detailing how this area of immunology is littered with misconceptions, due, in part, to misuse of terminology.
15. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14(2), 430-445 (2001).
16. Holmgren J, Adamsson J, Anjuère F et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett. 97(2), 181-188 (2005).
17. Ortolani C, Pastorello EA. Food allergies and food intolerances. Best Pract. Res. Clin. Gastroenterol. 20(3), 467-483 (2006).
18. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21(Suppl. 2), S89-S95 (2003).
19. Faria AM, Weiner HL. Oral tolerance and TGF-β-producing cells. Inflamm. Allergy Drug Targets 5(3), 179-190 (2006).
20. Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 23(15), 1804-1813 (2005).
21. Ferro VA, Carter KC. Mucosal immunization: successful approaches to targeting different tissues. Methods 38(2), 61-64 (2006).
22. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 58(1), 68-89 (2006).
23. Brody S. Declining HIV rates in Uganda: due to cleaner needles, not abstinence or condoms. Int. J. STD AIDS 15, 440-441 (2004).
24. Shah SM, Bonauto D, Silverstein B, Foley M. Workers' compensation claims for needlestick injuries among healthcare workers in washington state, 1996-2000. Infect. Control Hosp. Epidemiol. 26(9), 775-781 (2005).
25. Kunisawa J, Fukuyama S, Kiyono H. Mucosa-associated lymphoid tissues in the aerodigestive tract: their shared and divergent traits and their importance to the orchestration of the mucosal immune system. Curr. Mol. Med. 5(6), 557-572 (2005).
26. Kang W, Kudsk KA. Is there evidence that the gut contributes to mucosal immunity in humans? J. Parenter. Enteral Nutr. 31(3), 246-258 (2007).
27. Pabst R, Russell MW, Brandtzaeg P. Tissue distribution of lymphocytes and plasma cells and the role of the gut. Trends Immunol. 29(5), 206-208 (2008).
28. Miller H, Zhang J, Kuolee R et al. Intestinal M cells: the fallible sentinels? World J. Gastroenterol. 13(10), 1477-1486 (2007).
29. McGhee JR, Kunisawa J, Kiyono H. Gut lymphocyte migration: we are halfway 'home'. Trends Immunol. 28(4), 150-153 (2007).
30. Jang MH, Kweon MN, Iwatani K et al. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc. Natl Acad. Sci. USA 101(16), 6110-6115 (2004).
31. Novak N, Bieber T. Dendritic cells as regulators of immunity and tolerance. J. Allergy Clin. Immunol. 121(2 Suppl.), S370-S374 (2008).
32. Iwasaki A. Mucosal dendritic cells. Annu. Rev. Immunol. 25, 381-418 (2007).
33. Chirdo FG, Millington OR, Beacock-Sharp H, Mowat AM. Immunomodulatory dendritic cells in intestinal lamina propria. Eur. J. Immunol. 35(6), 1831-1840 (2005).
34. Rimoldi M, Rescigno M. Uptake and presentation of orally administered antigens. Vaccine 23(15), 1793-1796 (2005)
35. Eldridge JH, Hammond CJ, Meulbroek JA et al. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J. Control. Release 11, 205-214 (1990).
36. Matsunaga Y, Wakatsuki Y, Tabata Y et al. Oral immunization with size-purified microsphere beads as a vehicle selectively induces systemic tolerance and sensitization. Vaccine 19(4-5), 579-588 (2000).
37. Espuelas S, Irache JM, Gamazo C. Synthetic particulate antigen delivery systems for vaccination. Inmunologíca 24(2), 208-223 (2005).
38. Kiyono H, Fukuyama S. NALT- versus Peyer's-patch mediated mucosal immunity. Nat. Rev. Immunol. 4, 699-708 (2004).
39. Terahara K, Yoshida M, Igarashi O et al. Comprehensive gene expression profiling of Peyer's patch M cells, villous M-like cells, and intestinal epithelial cells. J. Immunol. 180(12), 7840-7846 (2008).
40. Lu S, Holmdahl R. Different therapeutic and bystander effects by intranasal administration of homologous type II and type IX collagens on the collagen-induced arthritis and pristaneinduced arthritis in rats. Clin. Immunol. 90(1), 119-127 (1999).
41. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6, 148-158 (2006).
42. Johansen FE, Baekkevold ES, Carlsen HS et al. Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils. Blood 106(2), 593-600 (2005).
43. Holmgrem J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11(4 Suppl.), 45-52 (2005). •• Excellent overview of advances in mucosal vaccines including the application of tolerance in vaccines against allergy and autoimmunity.
44. Belshe RB, Edwards KM, Vesikari T et al. CAIV-T Comparative Efficacy Study Group Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356(7), 685-696 (2007).
45. Lavelle EC, O'Hagan DT. Delivery systems and adjuvants for oral vaccines. Expert Opin. Drug Deliv. 3(6) 747-762 (2006).
46. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr. Drug Deliv. 4(4), 297-305 (2007).
47. Sharpe S, Hanke T, Tinsley-Bown A et al. Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara. Virology 313, 13-21 (2003).
48. Twaites BR, de las Heras Alarcon C, Cunliffe D et al. Thermo and pH responsive polymers as gene delivery vectors: effect of polymer architecture on DNA complexation in vitro. J. Control. Release 97, 551-566 (2004).
49. Mercier GT, Nehete PN, Passeri MF et al. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 25(52), 8687-8701 (2007).
50. O'Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2(9), 727-735 (2003). •• Excellent overview of adjuvants used in vaccines.
51. Pérez O, Bracho G, Lastre M et al. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol. Cell Biol. 82, 603-610 (2004).
52. Illum L. Bioadhesive formulations for nasal peptide delivery. In: Drug Delivery - Issues in Fundamentals, Novel Approaches and Development. Mathiowitz E, Lehr CM, Chickering D (Eds). Marcel Dekker, NY, USA 507-539 (1998).
53. Illum L. Nasal drug delivery - possibilities, problems and solutions. J. Control. Release 87(1-3), 187-198 (2003).
54. Perrie Y, Mohammed AR, Kirby DJ et al. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 364(2), 272-280 (2008).
55. Takeuchi H, Matsui Y, Sugihara H et al. Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs. Int. J. Pharm. 303, 160-170 (2005).
56. Tafaghodi M, Tabassi SAS, Jaafari MR. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int. J. Pharm. 319(1-2), 37-43 (2006).
57. Ninomiya A, Ogasawara K, Kajino K et al. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine 20, 3123-3129 (2002).
58. Lai YH, Wang C. Delivery strategies of melanoma vaccines: an overview. Expert Opin. Drug Deliv. 5(9), 979-1001 (2008).
59. Ricci M, Blasi P, Giovagnoli S et al. Leucinostatin-A loaded nanospheres: characterization and in vivo toxicity and efficacy evaluation. Int. J. Pharm. 275(1-2), 61-72 (2004).
60. Rothkopf C, Fahr A, Fricker G et al. Uptake of phosphatidylserine-containing liposomes by liver sinusoidal endothelial cells in the serum-free perfused rat liver. Biochim. Biophys. Acta 668, 10-16 (2005).
61. Racker E. Reconstitution of cytochrome oxidase vesicles and conferral of sensitivity to energy transfer inhibitors. J. Membr. Biol. 10, 221-235 (1972).
62. Lowell GH. Proteosomes, hydorohpobic anchors, iscoms and liposomes for improved presentation of peptides and protein vaccines. In: New Generation Vaccines. Woodrow GC, Levine MM (Eds). Marcel Dekker, NY, USA 141-160 (1990).
63. Oster P, Lennon D, O'Hallahan J et al. MeNZBTM: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria menningitidis serogroup B disease epidemic strain. Vaccine 23, 2191-2196 (2005).
64. Pérez O, Lastre M, Lapinet J et al. Immune response induction and new effector mechanisms possibly involved in protection of Cuban anti-meningococcal BC vaccine. Infect. Immun. 69, 4502-4508 (2001).
65. Boutriau D, Poolman J, Borrow R et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vaccine Immunol. 14(1), 65-73 (2007).
66. Arigita C, Jiskoot W, Westdijk J et al. Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines. Vaccine 22, 629-642 (2004).
67. Jones T, Cyr S, Allard F et al. Protollin™: a novel adjuvant for intranasal vaccines. Vaccine 22, 3691-3697 (2004).
68. Cyr SL, Jones T, Stoica-Popescu I et al. C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine. Vaccine 25(16), 3228-3232 (2007).
69. Pérez O, Lastre M, Cabrera O et al. New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand. J. Immunol. 66, 271-277 (2007).
70. Rodríguez T, Pérez O, Menager N et al. Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery. Vaccine 23, 1312-1321 (2005).
71. Pérez JL, Acevedo R, Fernández Y et al. A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in balb/c mice. Vaccine DOI: 10.1016/j.vaccine.2008.10.052 (2008) (Epub ahead of print).
72. Gould-Fogerite S, Kheiri MT, Zhang F et al. Targeting immune response induction with cochleate and liposome-based vaccines. Adv. Drug Deliv. Rev. 32, 273-287 (1998).
73. del Campo J, Lastre M, Bracho G et al. Immunological evaluation of bacterial derived cochleate and proteoliposome as mucosal adjuvants Vaccine 24(Suppl. 2), 50-51 (2006).
74. Bracho G, Lastre M, del Campo J et al. Proteoliposome derived cochleate as novel adjuvant. Vaccine 24(Suppl. 2), 30-31 (2006).
75. Shoemaker SD, Vanderlick TK. Calcium modulates the mechanical properties of anionic phospholipid membranes. J. Colloid Interface Sci. 266, 314-321 (2003).
76. Morein B, Sundquist B, Hoglund S et al. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308, 457-460 (1984).
77. Skene CD, Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods 40(1), 53-59 (2006).
78. Scheerlinck JP, Greenwood DL. Virus-sized vaccine delivery systems. Drug Discov. Today 13(19-20), 882-887 (2008).
79. Coulter R, Harris R, Davis D et al. Intranasal vaccination with ISCOMATRIX™ adjuvanted influenza vaccine. Vaccine 21, 946-949 (2003).
80. Brewer J, Alexander J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology 75(4), 570-575 (1992).
81. Rentel CO, Bouwstra JA, Naisbett B, Junginger HE. Niosomes as a novel peroral vaccine delivery system. Int. J. Pharm. 186(2), 161-167 (1999).
82. Sihorkar V, Vyas SP. Polysaccharide coated niosomes for oral drug delivery: formulation and in vitro stability studies. Pharmazie 55(2), 107-113 (2000).
83. Mann JFS, Ferro VA, Mullen AB et al. Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin. Vaccine 22(19), 2425-2429 (2004).
84. Singh P, Prabakaran D, Jain S et al. Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization. Int. J. Pharm. 278(2), 379-390 (2004).
85. Mann JFS, Scales HE, Shakir E et al. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 38(2), 90-95 (2006).
86. Shukla A, Khatri K, Gupta PN et al. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J. Pharm. Pharmaceut. Sci. 11(1), 59-66 (2008).
87. Vivona S, Gardy JL, Ramachandran S et al. Computer-aided biotechnology: from immuno-informatics to reverse vaccinology. Trends Biotechnol. 26(4) 190-200 (2008).
88. Huergo CC, Sierra VG, Gutierrez MM et al. US5597572 (1997).
89. Pérez Martín OG, Bracho Granados GR, Lastre González MSJB et al. OCPI23313 (2008).
90. Websites 201 WHO. Needle-removing and recycling of the plastic from auto-disable (AD) syringes www.who.int/immunization_safety/ waste_management/update/en/index3.html
91. US FDA product approval www.fda.gov/cber/approvltr/inflmed061703l.htm
92. Grand challenges in global health www.gcgh.org/pages/browsebytechnology. aspx#vaccines
93. Reuters. AVANT's single-dose oral Ty800 vaccine meets primary end points in Phase 2 study www.reuters.com/article/pressrelease/idus122362+01-apr- 2008+bw20080401
94. GelSite™ biotechnologies www.gelsite.com/newfiles/gelvac.html 206 DOR Biopharma Inc. BT-VACC™ (botulinum toxine vaccine) www.dorbiopharma.com/btvac.htm
95. Medicago product development www.medicago.com/en/product/
96. Biotechnology market news www.biotechnologymarketnews.com/2008/01/new- patent-awar.html
97. NanoBio corporation www.onemedplace.com/database/list/cid/5769/
98. Nasvax product pipeline www.nasvax.com/content. aspx?page= product_pipelinewww.vaxin.com/productdevelopment.htm
99. Vaccin product development. Intranasal influenza vaccine www.vaxin.com/ProductDevelopment.htm